Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2009-05-21
2011-10-04
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C424S646000
Reexamination Certificate
active
08030299
ABSTRACT:
Melanoma is a solid tumor that is notoriously resistant to chemotherapy, and its incidence is rapidly increasing. Recently, several signaling pathways have been demonstrated to contribute to melanoma tumorigenesis, including constitutive activation of MAP kinase, Akt and stat-3. The activation of multiple pathways may account in part for the difficulty in treatment of melanoma. In a recent screen of compounds, we found that an organopalladium complex showed significant antiproliferative activity against melanoma cells. This complex, tris(dibenzylideneacetone)dipalladium (Tris DBA), has activity against B16 murine and A375 human melanoma in vivo. Tris DBA inhibits several signaling pathways including activation of MAP kinase, Akt, stat-3 and S6 kinase activation. Tris(dibenzylideneacetone)dipalladium is thus a novel compound that is a member of a class of noble metal complexes with potential antitumor activity. Further preclinical evaluation of TrisDBA and related complexes is warranted.
REFERENCES:
patent: 5679697 (1997-10-01), Garnett et al.
patent: 5880149 (1999-03-01), Grinstaff et al.
patent: 6462075 (2002-10-01), Bowen et al.
patent: 6664272 (2003-12-01), Snyder et al.
patent: 6673843 (2004-01-01), Arbiser
patent: 2004/0176384 (2004-09-01), Snyder et al.
patent: 2005/0148599 (2005-07-01), Bowen et al.
patent: 2006/0106100 (2006-05-01), Caires et al.
Bauland et. al., Plastic and Reconstructive Surgery, 2006, American Society of Plastic Surgeons, vol. 117, issue 2, pp. 29e-35e.
de Villiers et. al., Virology, 2004, Elsevier, vol. 324, pp. 17-27.
Miller et. al., The New England Journal of Medicine, 2006, Massachusetts Medical Society, vol. 355, issue 1, pp. 51-65.
Rindfleisch et. al., American Family Physician, 2005, American Academy of Family Physicians, vol. 72, No. 6, pp. 1037-1047.
Ahmadzadeh,M. and Rosenberg,S.A. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients, Blood, 107: 2409-2414, 2006.
Arbiser et al., The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice, J. Am. Acad. Derm. pp. 925-929 (Jun. 1999).
Arbiser,J.L., et al., Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways, Proc.Natl.Acad.Sci.U.S.A, 94: 861-866, 1997.
Arbiser,J.L. Molecular regulation of angiogenesis and tumorigenesis by signal transduction pathways: evidence of predictable and reproducible patterns of synergy in diverse neoplasms, Semin.Cancer Biol., 14: 81-91, 2004.
Arbiser,J.L., et al., Curcumin is an in vivo inhibitor of angiogenesis, Mol.Med., 4: 376-383, 1998.
Atkins,M.B. Cytokine-based therapy and biochemotherapy for advanced melanoma, Clin.Cancer Res., 12: 2353s-2358s, 2006.
Bai,X., et al., Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo, J.Biol.Chem., 278: 35501-35507, 2003.
Bhoumik,A., et al., Inhibition of melanoma growth and metastasis by ATF2-derived peptides, Cancer Res., 64: 8222-8230, 2004.
Bromberg,J. Stat proteins and oncogenesis, J.Clin.lnvest, 109: 1139-1142, 2002.
Budakoti, A. et al., “Syntheses, characterization and in vitro antiamoebic activity of new Pd(II) complexes with 1 N-substituted thiocarbamoy1-3,5-diphenyl-2-pyrazoline derivatives,” Eur. J. Med. Chem. 42(4):544-51 (2007).
Budakoti, A. et al., “Synthesis and antiamoebic activity of new 1-n-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives and their Pd(II) complexes,” Eur. J. Medicinal Chem. 41:63-70 (2006).
Burdelya, L., et al., Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects, J.Immunol., 174: 3925-3931, 2005.
Cerimele, F., et al., Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma, Proc.Natl.Acad.Sci.U.S.A, 102: 175-179, 2005.
Cohen, C., et al., Mitogen-actived protein kinase activation is an early event in melanoma progression, Clin.Cancer Res., 8: 3728-3733, 2002.
Dhawan,P. and Richmond, A. A novel NF-kappa B-inducing kinase-MAPK signaling pathway up-regulates NF-kappa B activity in melanoma cells, J.Biol.Chem., 277: 7920-7928, 2002.
Dhawan, P., et al., Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression, Cancer Res., 62: 7335-7342, 2002.
Eisen,T., et al., Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis, Br.J.Cancer 95:581-86 (2006).
Eton, O. et al., A phase II study of “decrescendo” interleukin-2 plus interferon-a-2a in patients with progressive metastic melanoma after chemotherapy, Cancer 88(7):1703-09 (2000).
Fried, L. et al., “The reactive oxygen-driven tumor: relevance to melanoma,” The Authors, J. Compilation, Pigment Cell Melanoma Res. (2008).
Gabrilovich,D.I., et al., Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat.Med., 2: 1096-1103, 1996.
Garraway, L.A., et al., Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma, Nature, 436: 117-122, 2005.
Govindarajan, B., et al., Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling, J. Biol. Chem. 278:9790-95 (2003).
Govindarajan, B., et al., “Overexpression of Akt converts radial growth melanoma to vertical growth melanoma,” JCI Online First, publ. online http://www.jci.org (Feb. 22, 2007).
Haluska,F.G., et al., Genetic alterations in signaling pathways in melanoma, Clin.Cancer Res., 12: 2301s-2307s, 2006.
Hamilton,A.L., et al., Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle, J.Clin.Oncol., 23: 6107-6116, 2005.
Huang,S., et al., Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity, Cytokines Cell Mol.Ther., 6: 9-17, 2000.
International Preliminary Report on Patentability from corresponding PCT/US07/87741, mailed Jul. 2, 2009.
International Search Report from corresponding PCT/US07/87741, mailed May 1, 2008.
John, VD et al., “Antitumour activity of synthetic curcuminoid analogues (1,7-diary-1,6-heptadiene-3,5-diones) and their copper complexes,” Appl. Organometallic Chem. 20(8):477-82 (2006).
Karakousis,C.P. et al., cis-Dichlorodiammineplatinum(II) and DTIC in malignant melanoma, Cancer Treat.Rep., 63: 2009-2010, 1979.
Karakousis,C.P. et al., “Tourniquet infusion chemotherapy for extremity in-transit lesions in malignant melanoma,” Ann. surg. Onc. 4(6):506-10 (1997).
Khor,T.O., et al., Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice, Cancer Res., 66: 613-621, 2006.
King, M.J., and Sharma, R.K. N-myristoyl transferase assay using phosphocellulose paper binding. Anal. Biochem., 199: 149-153, 1991.
King, M.J. and Sharma, R.K. (1993) Identification, purification and characterization of a membrane-associated N-myristoyltransferase inhibitor protein from bovine brain. Biochem. J. 291, 635-639.
Legha, S.S. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy, Semin.Oncol., 24: S39-S43, 1997.
Larribere,L., Khaled,M., Tartare-Deckert,S., Busca,R., Luciano,F., Bille,K., Valony,G., Eychene, A., et al., P13K mediates protection against TRAIL-induced apoptosis in primary human melanocytes, Cell Death.Differ., 11: 1084-1091, 2004.
Lewis, K.D., et al., A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF, Cancer Invest, 23: 303-308, 2005.
Lewis, 'Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma, J. Clin. Oncology 24(19):3157-63 (2006).
Liu, A., et al., PSK and Trx80 inhibit B-c
Geary III William C.
Nutter & McClennen & Fish LLP
Padmanabhan Sreeni
Pihonak Sarah
LandOfFree
Palladium complexes inhibit N-myristoyltransferase activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Palladium complexes inhibit N-myristoyltransferase activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Palladium complexes inhibit N-myristoyltransferase activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4292253